Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
The USA’s Merck & Co has suffered a setback for its star immuno-oncology therapy Keytruda (pembrolizumab), in gastric cancer. 29 April 2019
Biotechnology
Shares in US biotech Portola Pharmaceuticals closed 3% up on Friday following news that the European Commission (EC) has granted conditional Marketing Authorization for Ondexxya (andexanet alfa). 29 April 2019
Biotechnology
The US Food and Drug Administration has approved Praluent (alirocumab) to reduce the risk of heart attack, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular (CV) disease. 29 April 2019
Biotechnology
Nightstar Therapeutics today announced that two leading independent proxy advisory firms, Institutional Shareholder Services (ISS) and Glass Lewis & Co have recommended that Nightstar shareholders vote "FOR" the proposals relating to the proposed acquisition of Nightstar by an affiliate of US biotech major Biogen in a transaction valued at $877 million, 26 April 2019
Biotechnology
Celgene reported net product sales of $4,024 million for the first quarter of 2019, a 14% increase from the same period in 2018. 26 April 2019
Biotechnology
US pharma major Eli Lilly yesterday announced that the company has been working to facilitate the withdrawal of Lartruvo (olaratumab) from the market for the treatment of advanced soft tissue sarcoma (STS). 26 April 2019
Biotechnology
Swiss pharma giant Roche has for a second time withdrawn its Premerger Notification and Report Form under the Hart-Scott-Rodino Act (the HSR Act) in connection with its pending acquisition of Spark Therapeutics under its previously announced tender offer to purchase all of the outstanding shares of common stock of Spark for $114.50 per share, a transaction valued at around $4.3 billion. 26 April 2019
Biotechnology
Shares of US biopharma AbbVie were up 2.33% at $80.50 in pre-market trading this morning, as the company released first-quarter financial results that beat consensus forecasts. 25 April 2019
Biotechnology
Buoyed by a good showing from its largest brands, Bristol-Myers Squibb (NYSE: BMY) announced first quarter revenues of $5.9 billion on Thursday, up 14% from the same period last year. 25 April 2019
Biotechnology
Kite has announced plans for a new facility in Frederick County, Maryland, which will produce innovative cell therapies for people with cancer. 25 April 2019
Biotechnology
The USA’s Centers for Medicare & Medicaid Services (CMS) has proposed a rule that focuses the agency’s efforts on a singular objective: transforming the healthcare delivery system through competition and innovation to provide patients with better value and results. 25 April 2019
Biotechnology
West Coast, USA-based Forge Therapeutics has inked a deal with Switzerland's Basilea Pharmaceutica to discover, develop, and commercialize novel antibiotic classes. 25 April 2019
Biotechnology
New data supporting the long-term safety of Cimzia (certolizumab pegol), the only Fc-free, PEGylated anti-tumor necrosis factor (TNF), in patients with moderate-to-severe plaque psoriasis, and new efficacy data for patients who show signs of psoriasis-related nail disease and those who had an inadequate early treatment response to Cimzia, were released today. 25 April 2019
Biotechnology
Shares in Biogen dropped almost 2% on Wednesday morning, despite an upbeat financial results statement which indicated higher-than-expected revenue and earnings. 24 April 2019
Biotechnology
Genome editing specialist Emendo Biotherapeutics has agreed a licensing deal with Takeda Pharmaceutical. 24 April 2019
Biotechnology
As was largely anticipated, the US Food and Drug Administration late on Tuesday approved Skyrizi (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor, for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. 24 April 2019
Biotechnology
Alder BioPharmaceuticals has submitted for US approval for eptinezumab, an investigational monoclonal antibody, and the firm’s lead candidate. 24 April 2019
Biotechnology
Russia’s Research Institute of Highly Pure Biopreparations, a St Petersburg-based producer of active ingredients and drugs, plans to invest up to $20 million in the launch of production of certain drugs against anemia, as well as some active ingredients, with the aim of their further exports, according to the company, reports The Pharma Letter’s local correspondent. 24 April 2019
Biotechnology
Privately-owned UK-based regenerative medicine company Rexgenero has provided an update on its Phase III studies of REX-001 to treat critical limb ischemia (CLI) in diabetes. 24 April 2019
Biotechnology
Positive interim results from a Phase III trial evaluating the effect of Novartis’ Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101) in Type 1 spinal muscular atrophy (SMA) patients is expected to make the case stronger for its approval and also its long-term use as a mainstream treatment option. 23 April 2019
All news
Biotechnology
AstraZeneca and Daiichi Sankyo’s breast cancer med Enhertu (trastuzumab deruxtecan) will be included in China’s state-run health insurance scheme from next year, boosting availability at the cost of reduced pricing. 29 November 2024
Biotechnology
Minghui Pharmaceutical has reported encouraging results from a Phase III trial of MH004 (tofacitinib etocomil) in mild to moderate atopic dermatitis (AD). 29 November 2024
Biotechnology
Allink Biotherapeutics, a Chinese start-up focused on bispecific antibody and antibody-drug conjugates (ADC), has raised $42 million in a financing round led by Lanchi Ventures. 29 November 2024
Biotechnology
China’s Innovent Biologics has announced that the updated 2024 National Reimbursement Drug List (NRDL) now includes Sintbilo (tafolecimab) injection, an anti-PCSK9 monoclonal antibody for the first time. The updated NRDL will be officially effective from January 1, 2025. 29 November 2024
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze